Why is Innoviva, Inc. ?
- OPERATING CASH FLOW(Y) Highest at USD 201.66 MM
- NET PROFIT(Q) At USD 32.68 MM has Grown at 339.19%
- DEBT-EQUITY RATIO (HY) Lowest at -27.14 %
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 25.58%, its profits have risen by 21.7% ; the PEG ratio of the company is 0.8
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Along with generating 25.58% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
How much should you buy?
- Overall Portfolio exposure to Innoviva, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Innoviva, Inc. for you?
Low Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 201.66 MM
At USD 32.68 MM has Grown at 339.19%
Lowest at -27.14 %
Highest at USD 1,030.83 MM
Highest at 2.54 times
Highest at USD 111.26 MM
Highest at USD 1.08
Grown by 13.73% (YoY
Lowest at USD 44.68 MM
Lowest at 40.16 %
Lowest at USD 35.56 MM
Here's what is working for Innoviva, Inc.
Net Profit (USD MM)
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Net Sales (USD MM)
EPS (USD)
Cash and Cash Equivalents
Inventory Turnover Ratio
Depreciation (USD MM)
Here's what is not working for Innoviva, Inc.
Operating Profit (USD MM)
Operating Profit to Sales
Pre-Tax Profit (USD MM)
Raw Material Cost as a percentage of Sales






